ID   MDA-MB-231sci
AC   CVCL_XE60
DR   cancercelllines; CVCL_XE60
DR   CCRID; 4201PAT-CCTCC00312
DR   Wikidata; Q95987394
RX   Patent=CN102071168A;
CC   Group: Patented cell line.
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200955.
CC   Population: Caucasian.
CC   Characteristics: Highly metastatic.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0062 ! MDA-MB-231
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 06-09-19; Last updated: 05-10-23; Version: 10
//
RX   Patent=CN102071168A;
RA   Liu L., Yao M., Kong H.-W., Zhu Y.-X., Wang X.-M., Zhao F.-Y.,
RA   Yan M.-X.;
RT   "High metastasis human breast carcinoma cell subline and establishing
RT   method thereof.";
RL   Patent number CN102071168A, 25-May-2011.
//